Royalty Report: Drugs, Pharmaceuticals, Fibrosis – Collection: 44335

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Fibrosis

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 44335

License Grant
The company executed an agreement with the University,  for an exclusive license to those rights the University may own in certain patents and patent applications relating to GBT440 and GBT440 analogs.
License Property
Product candidate, GBT440, is being developed as a once-daily, oral therapy for sickle cell disease, or SCD, and currently evaluating GBT440 in both healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind clinical trial that we characterize as a Phase 1/2 clinical trial. GBT440 targets the underlying mechanism of red blood cell sickling, which we believe provides the potential to treat SCD rather than only its associated symptoms. In addition to GBT440 for the treatment of SCD, we are leveraging our deep scientific expertise in the chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis, and hereditary angioedema, or HAE.
Field of Use
This Agreement pertains to the drug industry.

IPSCIO Record ID: 286301

License Grant
Licensor grants the Licensee of Japan the exclusive right to commercialize BCX7353 in Japan for the prevention of HAE attacks.
License Property
BCX7353 is in drug class: Oral Serine Protease Inhibitor Targeting Plasma Kallikrein (once-daily treatment).  Licensor is a biotechnology company that discovers novel, oral, small-molecule medicines.
Field of Use
The field of use is for the therapeutic area of Hereditary Angioedema or HAE.  Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling (angioedema)

IPSCIO Record ID: 275290

License Grant
As part of the 10-year global collaboration, Licensee gains rights to GLPG1690, Licensors Phase 3 candidate for idiopathic pulmonary fibrosis. Licensee also receives option rights for GLPG1972, a Phase 2b candidate for osteoarthritis, in the United States.  In addition, Licensee receives option rights on all of Licensors other current and future clinical programs outside of Europe.  Through this agreement, Licensee will gain access to an innovative portfolio of compounds, including six molecules currently in clinical trials, more than 20 preclinical programs and a proven drug discovery platform.
License Property
Both GLPG1690 and GLPG1972 are first-in-class compounds, candidate for idiopathic pulmonary fibrosis.
Field of Use
Idiopathic pulmonary fibrosis is a type of chronic lung disease characterized by a progressive and irreversible decline in lung function.

GLPG1972 is a Phase 2b candidate for osteoarthritis.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.